IL237634A0 - Multimeric oligonucleotide compounds - Google Patents
Multimeric oligonucleotide compoundsInfo
- Publication number
- IL237634A0 IL237634A0 IL237634A IL23763415A IL237634A0 IL 237634 A0 IL237634 A0 IL 237634A0 IL 237634 A IL237634 A IL 237634A IL 23763415 A IL23763415 A IL 23763415A IL 237634 A0 IL237634 A0 IL 237634A0
- Authority
- IL
- Israel
- Prior art keywords
- oligonucleotide compounds
- multimeric oligonucleotide
- multimeric
- compounds
- oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701351P | 2012-09-14 | 2012-09-14 | |
| US201361783272P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/059772 WO2014043544A1 (en) | 2012-09-14 | 2013-09-13 | Multimeric oligonucleotide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237634A0 true IL237634A0 (en) | 2015-04-30 |
Family
ID=50278726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237634A IL237634A0 (en) | 2012-09-14 | 2015-03-09 | Multimeric oligonucleotide compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20150247141A1 (enExample) |
| EP (1) | EP2895200B1 (enExample) |
| JP (1) | JP2015529469A (enExample) |
| AU (3) | AU2013315225B2 (enExample) |
| CA (1) | CA2884608C (enExample) |
| DK (1) | DK2895200T3 (enExample) |
| IL (1) | IL237634A0 (enExample) |
| WO (1) | WO2014043544A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| EP2850186B1 (en) | 2012-05-16 | 2018-12-19 | Translate Bio MA, Inc. | Compositions and methods for modulating smn gene family expression |
| US10058623B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating UTRN expression |
| CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
| AU2013262700A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| US10174323B2 (en) | 2012-05-16 | 2019-01-08 | The General Hospital Corporation | Compositions and methods for modulating ATP2A2 expression |
| WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| MX2016002044A (es) * | 2013-08-16 | 2016-08-17 | Rana Therapeutics Inc | Composiciones y metodos para modular el acido ribonucleico. |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| KR102287532B1 (ko) | 2014-01-30 | 2021-08-11 | 에프. 호프만-라 로슈 아게 | 생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물 |
| BR112017001931A2 (pt) | 2014-08-07 | 2017-11-28 | Regulus Therapeutics Inc | direcionamento de micrornas para distúrbios metabólicos |
| US20200230251A1 (en) * | 2014-08-14 | 2020-07-23 | Friedrich-Schiller-Universitaet Jena | Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects |
| GB201421379D0 (en) * | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
| WO2016130943A1 (en) * | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| HUE050441T2 (hu) | 2015-04-03 | 2020-12-28 | Univ Massachusetts | Huntingtin-mRNS célzására szolgáló oligonukleotid-vegyületek |
| JP6892433B2 (ja) | 2015-04-03 | 2021-06-23 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 十分に安定化された非対称ｓｉｒｎａ |
| IL316159A (en) * | 2015-06-15 | 2024-12-01 | Mpeg La Llc | Defined Oligonucleotide Multimers and Methods for Manufacture Thereof |
| WO2017007886A2 (en) * | 2015-07-08 | 2017-01-12 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting dux4 gene expression and uses thereof |
| CA2995110A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US11530409B2 (en) * | 2016-01-26 | 2022-12-20 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| AU2017210726B2 (en) | 2016-01-31 | 2023-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| JP7183167B2 (ja) | 2017-02-06 | 2022-12-05 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | 減少した腎クリアランスを有する多量体オリゴヌクレオチド |
| TWI830693B (zh) | 2017-02-06 | 2024-02-01 | 日商日產化學工業股份有限公司 | 單股寡核苷酸 |
| WO2018182008A1 (ja) * | 2017-03-31 | 2018-10-04 | 株式会社ボナック | 遺伝子発現制御機能を有する環状型核酸分子 |
| JP7246729B2 (ja) * | 2017-05-18 | 2023-03-28 | 国立大学法人京都大学 | 脊髄小脳変性症３６型の予防又は治療用組成物 |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| AU2018307294B2 (en) | 2017-07-26 | 2025-04-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US20200347385A1 (en) * | 2017-11-09 | 2020-11-05 | The University Of Tokyo | METHOD FOR mRNA STABILIZATION |
| WO2019199945A1 (en) * | 2018-04-10 | 2019-10-17 | Board Of Regents, The University Of Texas System | Dna-barcoded antigen multimers and methods of use thereof |
| EP3822351A4 (en) * | 2018-05-31 | 2023-03-29 | Korea University Research and Business Foundation | Modified nucleic acid inhibiting micro rna, and use thereof |
| US11168141B2 (en) * | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| AU2019316640A1 (en) | 2018-08-10 | 2021-03-18 | University Of Massachusetts | Modified oligonucleotides targeting SNPs |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| SG11202103938UA (en) | 2018-11-02 | 2021-05-28 | Biomarin Tech Bv | Bispecific antisense oligonucleotides for dystrophin exon skipping |
| MX2021006726A (es) | 2018-12-07 | 2021-09-23 | Univ Oxford Innovation Ltd | Enlazadores. |
| US11492619B2 (en) | 2019-01-18 | 2022-11-08 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| CA3136720A1 (en) | 2019-04-17 | 2020-10-22 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US20230114023A1 (en) * | 2019-07-30 | 2023-04-13 | Mpeg La, L.L.C. | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
| BR112022002307A2 (pt) | 2019-08-09 | 2022-06-28 | Univ Massachusetts | Oligonucleotídeos quimicamente modificados que têm como alvo snps |
| WO2021030768A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
| JP2022550248A (ja) | 2019-08-14 | 2022-12-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 分子に連結された細胞外小胞及びその使用 |
| EP4013878A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicle-aso constructs targeting cebp/beta |
| WO2021030781A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| WO2021030773A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
| WO2021030776A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| KR102270700B1 (ko) * | 2019-11-01 | 2021-06-30 | 한국과학기술연구원 | 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용 |
| WO2021222635A2 (en) * | 2020-04-30 | 2021-11-04 | Mpeg La, L.L.C. | Multimeric oligonucleotides with divided strands |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
| WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| EP4229208A4 (en) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF |
| EP4237436A4 (en) * | 2020-10-29 | 2025-09-10 | Garcia Blanco Mariano A | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATION THERAPY FOR CANCERS |
| US20240189430A1 (en) | 2021-02-17 | 2024-06-13 | Lonza Sales Ag | Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety |
| MX2023015523A (es) | 2021-06-23 | 2024-03-11 | Univ Massachusetts | Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos. |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| EP4441224A1 (en) * | 2021-12-03 | 2024-10-09 | Quralis Corporation | Gapmer antisense oligonucleotides with modified backbone chemistries |
| JP2025509552A (ja) * | 2022-03-17 | 2025-04-11 | アリゴス セラピューティクス，インコーポレーテッド | 修飾ギャップマーオリゴマー及びその使用方法 |
| JPWO2024005156A1 (enExample) * | 2022-06-29 | 2024-01-04 | ||
| CA3261203A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharma | COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| CN120500498A (zh) | 2022-11-14 | 2025-08-15 | 瑞泽恩制药公司 | 用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法 |
| CN120936364A (zh) | 2023-01-27 | 2025-11-11 | 瑞泽恩制药公司 | 修饰的弹状病毒糖蛋白及其用途 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5965722A (en) | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
| WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
| US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
| US20070032446A1 (en) | 1991-12-24 | 2007-02-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| DK0618925T4 (da) | 1991-12-24 | 2012-07-09 | Isis Pharmaceuticals Inc | Antisense-oligonukleotider |
| TW244371B (enExample) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| CA2154578A1 (en) | 1993-01-25 | 1994-08-04 | Ekambar R. Kandimalla | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
| PL328563A1 (en) | 1996-02-14 | 1999-02-01 | Isis Pharmaceuticals Inc | Oligonucleotides of modified sugar residues |
| US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
| KR20000065690A (ko) | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법 |
| US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| CA2385853A1 (en) | 1999-10-04 | 2001-04-12 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
| WO2001048190A2 (en) | 1999-12-23 | 2001-07-05 | Exiqon A/S | Therapeutic uses of lna-modified oligonucleotides |
| US6602857B1 (en) | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| ATE293688T1 (de) | 2000-09-06 | 2005-05-15 | Univ Mcgill | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide |
| EP1416972B1 (en) | 2000-11-09 | 2012-02-08 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| DE60216798T2 (de) * | 2001-10-29 | 2007-10-18 | Mcgill University, Montreal | Azyklische linker enthaltende oligonukleotide und deren verwendungen |
| CA2475388A1 (en) * | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| US20080207542A1 (en) | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| DK2264172T3 (da) | 2002-04-05 | 2017-11-27 | Roche Innovation Ct Copenhagen As | Oligomerforbindelser til modulering af HIF-1á-ekspression |
| US20030228690A1 (en) | 2002-06-10 | 2003-12-11 | Isis Pharmaceuticals Inc. | Antisense modulation of IL-1 receptor-associated kinase-1 expression |
| US7507808B2 (en) | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
| WO2004044133A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| DE60329220D1 (de) | 2002-11-18 | 2009-10-22 | Santaris Pharma As | Antisense-entwurf |
| CA2515644A1 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| FR2853663B1 (fr) | 2003-04-14 | 2007-08-31 | Aventis Pharma Sa | Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine |
| WO2004112565A2 (en) | 2003-06-25 | 2004-12-29 | Quark Biotech, Inc. | Diagnosis and treatment of liver, pulmonary and cardiac fibrosis |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| SG123799A1 (en) | 2003-10-30 | 2006-07-26 | Coley Pharm Gmbh | C-class oligonucleotide analogs with enchanced immunostimulatory potency |
| US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| EP1706489B9 (en) * | 2003-12-23 | 2011-01-05 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
| EP1713332A4 (en) | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| US20050197310A1 (en) | 2004-01-30 | 2005-09-08 | Orna Mor | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
| WO2005094370A2 (en) | 2004-03-29 | 2005-10-13 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
| KR20070085113A (ko) | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법 |
| CA2568735A1 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| DE102005036654A1 (de) | 2005-08-04 | 2007-02-15 | Bayer Materialscience Ag | Selbstvernetzende PUR-Dispersionen mit Uretdionstruktur |
| WO2007056829A1 (en) | 2005-11-21 | 2007-05-24 | Johnson & Johnson Research Pty Limited | Multitargeting interfering rnas having two active strands and methods for their design and use |
| WO2007133812A2 (en) | 2005-12-30 | 2007-11-22 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
| CA2640058C (en) | 2006-01-27 | 2018-04-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US8586554B2 (en) | 2006-05-05 | 2013-11-19 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PTP1B |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| CA2667055C (en) | 2006-10-18 | 2017-05-09 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| US20080311040A1 (en) | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| CA2694973A1 (en) * | 2007-08-15 | 2009-02-19 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
| CA2701639A1 (en) | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Modulating gene expression with agrna and gapmers targeting antisense transcripts |
| PL2623598T3 (pl) | 2007-10-04 | 2018-12-31 | Roche Innovation Center Copenhagen A/S | Micromir |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009124295A2 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| WO2009124341A1 (en) | 2008-04-07 | 2009-10-15 | The University Of Queensland | Rna molecules and uses thereof |
| CA2635187A1 (en) | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
| US20110172292A1 (en) | 2008-06-30 | 2011-07-14 | Hansen Jens Bo Rode | Antidote oligomers |
| CA2739464C (en) | 2008-10-03 | 2020-03-31 | Opko Curna, Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| EP2349210B1 (en) | 2008-10-16 | 2015-03-18 | Marina Biotech, Inc. | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
| US20120016007A1 (en) | 2009-02-04 | 2012-01-19 | Dong Ki Lee | Small interference rna complex with increased intracellular transmission capacity |
| WO2010120969A1 (en) * | 2009-04-15 | 2010-10-21 | Board Of Regents, The University Of Texas System | Targeting of the mir-30 family and let-7 family as a treatment for heart disease |
| WO2011009624A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| SI2470656T1 (sl) * | 2009-08-27 | 2015-07-31 | Idera Pharmaceuticals, Inc. | Sestavek za inhibicijo ekspresije genov in njegova uporaba |
| EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| JP6141018B2 (ja) | 2009-12-24 | 2017-06-07 | バイオマリン テクノロジーズ ベー．フェー． | 炎症性障害を治療するための分子 |
| WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| WO2011130371A1 (en) | 2010-04-13 | 2011-10-20 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
| DK2560683T4 (da) * | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| ES2625689T3 (es) | 2010-04-29 | 2017-07-20 | Ionis Pharmaceuticals, Inc. | Modulación de la expresión de transtiretina |
| EP2582397A4 (en) | 2010-06-15 | 2014-10-29 | Isis Pharmaceuticals Inc | COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS |
| GB201010557D0 (en) | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
| EP2595663A4 (en) | 2010-07-19 | 2014-03-05 | Isis Pharmaceuticals Inc | MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| EP3254700B1 (en) | 2012-03-04 | 2019-10-23 | Bonac Corporation | Micro-rna inhibitor |
| CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
| EA201492119A1 (ru) | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии apoa1 и abca1 |
| BR112014028646A2 (pt) | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | Composições e métodos para modulação da expressão de pten |
| JP2015518714A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
| US10174323B2 (en) | 2012-05-16 | 2019-01-08 | The General Hospital Corporation | Compositions and methods for modulating ATP2A2 expression |
| WO2014025887A1 (en) * | 2012-08-07 | 2014-02-13 | The General Hospital Corporation | Selective reactivation of genes on the inactive x chromosome |
| WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| EP3406718A1 (en) | 2012-11-15 | 2018-11-28 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| AU2015346042A1 (en) | 2014-11-14 | 2017-04-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
-
2013
- 2013-09-13 WO PCT/US2013/059772 patent/WO2014043544A1/en not_active Ceased
- 2013-09-13 JP JP2015532097A patent/JP2015529469A/ja active Pending
- 2013-09-13 US US14/428,073 patent/US20150247141A1/en not_active Abandoned
- 2013-09-13 CA CA2884608A patent/CA2884608C/en active Active
- 2013-09-13 EP EP13837395.6A patent/EP2895200B1/en active Active
- 2013-09-13 DK DK13837395.6T patent/DK2895200T3/da active
- 2013-09-13 AU AU2013315225A patent/AU2013315225B2/en active Active
-
2015
- 2015-03-09 IL IL237634A patent/IL237634A0/en unknown
- 2015-04-28 US US14/698,166 patent/US20150315586A1/en not_active Abandoned
- 2015-04-28 US US14/698,115 patent/US9790494B2/en active Active
-
2017
- 2017-09-08 US US15/698,754 patent/US10844375B2/en active Active
-
2019
- 2019-02-06 AU AU2019200789A patent/AU2019200789B2/en active Active
-
2021
- 2021-05-18 AU AU2021203173A patent/AU2021203173B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2895200T3 (da) | 2020-02-10 |
| US20150247141A1 (en) | 2015-09-03 |
| CA2884608C (en) | 2025-05-20 |
| AU2013315225A1 (en) | 2015-04-02 |
| AU2019200789B2 (en) | 2021-04-01 |
| US20150315585A1 (en) | 2015-11-05 |
| US9790494B2 (en) | 2017-10-17 |
| US20150315586A1 (en) | 2015-11-05 |
| US10844375B2 (en) | 2020-11-24 |
| JP2015529469A (ja) | 2015-10-08 |
| EP2895200A1 (en) | 2015-07-22 |
| AU2021203173A1 (en) | 2021-06-10 |
| WO2014043544A1 (en) | 2014-03-20 |
| AU2013315225B2 (en) | 2018-11-08 |
| AU2021203173B2 (en) | 2025-01-30 |
| AU2019200789A1 (en) | 2019-02-21 |
| CA2884608A1 (en) | 2014-03-20 |
| US20180030444A1 (en) | 2018-02-01 |
| EP2895200A4 (en) | 2016-08-31 |
| EP2895200B1 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268013A (en) | Tetrahydropyrazolopyrimidine compounds | |
| IL237634A0 (en) | Multimeric oligonucleotide compounds | |
| IL231535A0 (en) | Multimeric oligonucleotide compounds | |
| SG11201403935VA (en) | Imidazopyrrolidinone compounds | |
| IL237341A0 (en) | Compounds that promote neurogenesis | |
| GB201209138D0 (en) | Compounds | |
| GB201214750D0 (en) | Compounds | |
| GB201215357D0 (en) | Compounds | |
| EP2828262A4 (en) | IMIDAZOTRIAZINONVERBINDUNGEN | |
| GB201204985D0 (en) | Compounds | |
| GB201204125D0 (en) | Compounds | |
| ZA201500778B (en) | Compounds | |
| SI2836495T1 (sl) | Spojine tetrahidropirolotiazina | |
| GB201209096D0 (en) | Compounds | |
| GB201217310D0 (en) | Compounds | |
| GB201223429D0 (en) | Compounds | |
| GB201220029D0 (en) | Compounds | |
| GB201219819D0 (en) | Compounds | |
| GB201218799D0 (en) | Compounds | |
| GB201218776D0 (en) | Compounds | |
| GB201218758D0 (en) | Compounds | |
| GB201218018D0 (en) | Compounds | |
| GB201217290D0 (en) | Compounds | |
| GB201217311D0 (en) | Compounds | |
| GB201217312D0 (en) | Compounds |